Reinforced Learning Model Can Improve Sensitivity of Skin Cancer Diagnosis
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 9, 2023 -- Incorporating human preferences into an image-based diagnostic algorithm can improve artificial intelligence (AI)-based decision support, according to a study published online July 27 in Nature Medicine.
Catarina Barata, Ph.D., from the Instituto Superior Técnico in Lisbon, Portugal, and colleagues examined whether human preferences can improve diagnostic AI-based decision support using the example of skin cancer diagnosis. Nonuniform rewards and penalties based on expert-generated tables were utilized, balancing the benefits and harms of diagnostic errors; these were applied using reinforcement learning to find a strategy that maximized cumulative rewards while considering both clinician and patient preferences.
The researchers found that the reinforcement learning model improved the sensitivity for melanoma from 61.4 to 79.5 percent and for basal cell carcinoma from 79.4 to 87.1 percent compared with supervised learning. There was a reduction noted in AI overconfidence, while accuracy was maintained. The rate of correct diagnoses made by dermatologists increased by 12.0 percent with reinforcement learning; the rate of optimal management decisions increased from 57.4 to 65.3 percent.
"The AI learned to take into account not only image-based features, but also consequences of misdiagnosis in the assessment of benign and malignant skin manifestations," lead author Harald Kittler, M.D., from the Medical University of Vienna, said in a statement. "This, in turn, helps physicians make more accurate decisions tailored to individual patients in complex medical scenarios."
Several authors disclosed financial ties to medical technology companies.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Non-Hispanic Black Melanoma Patients Present With Advanced Disease
WEDNESDAY, May 15, 2024 -- Non-Hispanic Black (NHB) melanoma patients have distinct tumor characteristics, presenting with more advanced disease and exhibiting worse outcomes...
Delayed Melanoma Care During Pandemic Proved Costly
TUESDAY, Feb. 27, 2024 -- Delays in melanoma diagnoses due to COVID-19 pandemic lockdowns were associated with a significant burden, including years of life lost and costs...
Amtagvi Approved by the FDA for Treatment of Advanced Melanoma
TUESDAY, Feb. 20, 2024 -- Amtagvi (lifileucel) has been approved by the U.S. Food and Drug Administration for the treatment of advanced melanoma. Amtagvi becomes the first...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.